Company Overview
DBV Technologies
DBVT is a clinical-stage biotech developing epicutaneous immunotherapy (EPIT) via the Viaskin® patch for food allergies—an easy, non-invasive approach for pediatrics.
Key Catalysts
Phase 3 Win (VITESSE): VIASKIN Peanut achieved 46.6% response vs. 14.8% placebo in children 4–7, validating efficacy and safety ahead of a planned BLA in H1 2026.
Regulatory & Funding Momentum: Warrant exercises bolster cash; plans to expand into younger age groups increase addressable market.
Durability & Platform Potential: Long-term extension data support sustained benefit and optionality across multiple food allergies.
Why It Matters
Non-invasive, patch-based therapy = high caregiver/child acceptance
Clear regulatory path plus broader age expansion → larger, earlier TAM
Platform line-of-sight beyond peanut to multi-allergen pipeline
Investment Outlook
Bullish above: $14.50–$15.00
Target: $28–$30 — supported by Phase 3 efficacy, upcoming BLA, and platform durability.
#DBVT #Viaskin #EPIT #FoodAllergy #Pediatrics #Biotech
DBV Technologies
DBVT is a clinical-stage biotech developing epicutaneous immunotherapy (EPIT) via the Viaskin® patch for food allergies—an easy, non-invasive approach for pediatrics.Key Catalysts
Phase 3 Win (VITESSE): VIASKIN Peanut achieved 46.6% response vs. 14.8% placebo in children 4–7, validating efficacy and safety ahead of a planned BLA in H1 2026.
Regulatory & Funding Momentum: Warrant exercises bolster cash; plans to expand into younger age groups increase addressable market.
Durability & Platform Potential: Long-term extension data support sustained benefit and optionality across multiple food allergies.
Why It Matters
Non-invasive, patch-based therapy = high caregiver/child acceptance
Clear regulatory path plus broader age expansion → larger, earlier TAM
Platform line-of-sight beyond peanut to multi-allergen pipeline
Investment Outlook
Bullish above: $14.50–$15.00
Target: $28–$30 — supported by Phase 3 efficacy, upcoming BLA, and platform durability.
#DBVT #Viaskin #EPIT #FoodAllergy #Pediatrics #Biotech
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.